Abstract 2218: Quantitative multiplex analysis of immune checkpoint protein expression in circulation and in the tumor microenvironment

Immune checkpoint inhibitors have been proven to be an effective method in improving antitumor immune response. Many immune checkpoint proteins are expressed as soluble forms in circulation and in the tumor and tumor microenvironment. Here we report the development of bead-based Luminex multiplex as...

Full description

Saved in:
Bibliographic Details
Published in:Cancer research (Chicago, Ill.) Ill.), 2017-07, Vol.77 (13_Supplement), p.2218-2218
Main Authors: Lie, Wen-Rong, Mistry, Jehangir
Format: Article
Language:English
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Immune checkpoint inhibitors have been proven to be an effective method in improving antitumor immune response. Many immune checkpoint proteins are expressed as soluble forms in circulation and in the tumor and tumor microenvironment. Here we report the development of bead-based Luminex multiplex assays for the quantitative profiling of co-inhibitory and co-stimulating immune checkpoint proteins CTLA-4, PD-1, TIM-3, LAG-3, HVEM. GITRL, BTLA, CD27, CD28, CD40, GITR, PD-L1, B7-1/CD80, B7-2/CD86, and ICOS. In order to explore the use of soluble immune checkpoint proteins as putative cancer biomarkers, we used these multiplex assays to measure checkpoint protein levels in serum samples from breast cancer patients, colon cancer patients, and a corresponding set of normal serum samples. Analysis of the soluble checkpoint protein signatures generated from this multiplex approach revealed a significantly elevated level of soluble TIM-3 protein in the breast cancer serum samples and in the colon cancer serum samples compared to the healthy serum controls (p
ISSN:0008-5472
1538-7445
DOI:10.1158/1538-7445.AM2017-2218